A chemoimmunotherapy combination with the programmed death ligand 1 (PD-L1) inhibitor atezolizumab prolonged progression-free survival in women with metastatic triple-negative breast cancer, an aggressive cancer with poor outcomes, according to a trial in the New England Journal of Medicine.
The 902 women with untreated metastatic triple-negative breast cancer were randomly assigned to receive atezolizumab plus nanoparticle albumin-bound (nab)–paclitaxel, or placebo plus nab-paclitaxel. Participants continued the regimen until their cancer progressed or adverse effects became too toxic.
Slomski A. Chemoimmunotherapy for Triple-Negative Breast Cancer. JAMA. 2018;320(24):2521. doi:10.1001/jama.2018.20159
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: